Current Report Filing (8-k)
20 Juni 2023 - 9:37PM
Edgar (US Regulatory)
0001601280
false
0001601280
2023-06-14
2023-06-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
———————
FORM 8-K
———————
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 14, 2023
———————
MediXall Group, Inc.
(Exact name of registrant as specified in
its charter)
———————
| Nevada |
333-186282 |
33-0864127 |
| (State or Other Jurisdiction |
(Commission |
(I.R.S. Employer |
| of Incorporation) |
File Number) |
Identification No.) |
2929
East Commercial Blvd., PH-D, Fort Lauderdale, Florida 33308
(Address of Principal Executive Office) (Zip Code)
(954) 440-4678
(Registrant’s telephone number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| N/A |
N/A |
N/A |
Indicate by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
| Emerging growth company ☐ |
|
If an emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 14, 2023, MediXall
Group, Inc. (the "Company") received the resignation of Michael J. Swartz as President, Secretary and Board Member, effective
June 14, 2023. Mr. Swartz’s resignation was not a result of a disagreement relating to the registrant’s
operations, policies or practices. Mr. Swartz’s resignation as President, Secretary and Board Member is accepted by the board.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| |
|
|
| 104 |
|
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
MediXall Group Inc. |
| |
|
|
| |
|
|
| Dated: June 20, 2023 |
By: |
/s/ Travis Jackson |
| |
Name: |
Travis Jackson |
|
Title: |
Chief Executive Officer |
MediXall (CE) (USOTC:MDXL)
Historical Stock Chart
Von Jan 2025 bis Feb 2025
MediXall (CE) (USOTC:MDXL)
Historical Stock Chart
Von Feb 2024 bis Feb 2025
